Important: This product is not authorized for administration until further notice by the FDA.
Labeler
Vaccine Procedure
Payment Allowance
Effective From
Effective To
Footnotes
My Fee
Eli Lilly
intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
$309.60
2021-02-09
2021-05-05
[3][8][9]
(your fee)
Eli Lilly
intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
$450.00
2021-05-06
2022-01-24
[3][8][9]
(your fee)
[3] These rates will be geographically adjusted for many providers.
[8] On September 16, 2021, the FDA revised the EUA for bamlanivimab and etesevimab, administered together, to allow its use for post-exposure prophylaxis (PEP) in certain adult and pediatric patients. Providers and suppliers should use Q0245 and M0245 or M0246 to bill for administering bamlanivimab and etesevimab for PEP.
[9] On January 24, 2022, the FDA announced that, due to the high frequency of the Omicron variant, this product isn’t currently authorized in any U.S region and may not be administered for treatment or post-exposure prevention of COVID-19 under the EUA until further notice by the FDA.
Quick, Current, Complete - www.findacode.com